Last reviewed · How we verify
NCT05305534
QIAstat-Dx® BCID Plus AMR Panels Clinical Performance Study
trial testing QIAstat-Dx® BCID GN and GPF Plus AMR Panels in Blood Disease in 2,142 participants. Completed in 25 August 2025.
10 April 2025
Quick facts
| Lead sponsor | QIAGEN Gaithersburg, Inc |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,142 |
| Start date | 1 December 2023 |
| Primary completion | 10 April 2025 |
| Estimated completion | 25 August 2025 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- QIAstat-Dx® BCID GN and GPF Plus AMR Panels
Conditions studied
- Blood Disease — all drugs for Blood Disease →
Sponsor
QIAGEN Gaithersburg, Inc — full company profile →
Who can join
Eligibility, any sex, with Blood Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study for performance evaluation of the QIAstat-Dx® BCID Plus AMR GPF-Panel and the QIAstat Dx® BCID Plus AMR GN-Panel in comparison with other chosen comparator methods
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05305534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Blood Disease
Currently open trials in the same condition.
- NCT03848962 — Collection and Distribution of Biospecimens for Novel Research Uses · recruiting
Other QIAGEN Gaithersburg, Inc trials
Trials by the same sponsor.
- NCT06360757 — Clinical Evaluation of the NeuMoDx SARS-CoV-2 Assay (COVID-19) · terminated
- NCT06645236 — DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit · NA · recruiting
- NCT05733559 — QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study · completed
- NCT06681025 — Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients · completed
- NCT05155553 — QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05305534 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by QIAGEN Gaithersburg, Inc
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05305534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing